SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes

Kenta Nonomura, Katsumi Iizuka, Yayoi Kuwabara-Ohmura, Daisuke Yabe

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.

Original languageEnglish
Pages (from-to)1535-1539
Number of pages5
JournalInternal Medicine
Volume59
Issue number12
DOIs
Publication statusPublished - 15-06-2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes'. Together they form a unique fingerprint.

Cite this